Higher Rate of Bladder Neck Incompetence in Mixed Urinary Incontinence

Patients with mixed urinary incontinence (MUI) have a higher rate of bladder neck incompetence (BNI), according to a study published online Sept. 29 in the World Journal of Urology. Yu-Chen Chen, from the Kaohsiung Medical University in Taiwan, and colleagues conducted a retrospective analysis involving 184 patients with stress UI (SUI), MUI, urge UI (UUI), or dry overactive bladder (OAB) who underwent transrectal ultrasound between 2017 and 2022. In all included patients, the presence of BNI and urethral incompetence was recorded. Read more.

Source: Medical Xpress, November 1, 2023

Myrbetriq Plus Pelvic Floor Exercises Fail to Ease Overactive Bladder

Combining Myrbetriq (mirabegron) with modifications like pelvic floor exercises failed to ease overactive bladder symptoms in people with Parkinson’s disease in a pilot clinical trial, the study’s main goal. But the treatment, approved for overactive bladder, when used with such behavioral modifications did increase the amount of urine patients were able to expel with each urination, relative to patients using only pelvic floor exercise. But this benefit was temporary. Read more.

Source: Parkinson’s News Today, December 7, 2022

Symptomatic Covid-19 Infection Is Associated With An Increased Risk Of Overactive Bladder Symptoms

A new study finds that symptomatic Covid-19 infection is associated with the risk of developing or exacerbating overactive bladder symptoms. As an overlooked area of study, only a handful of investigations have focused on the impact of Covid-19 infection on the urinary system. Previous studies have found increased urinary tract symptoms, including the frequency, urgency, and waking up to urinate, post Covid-19 infection; they attributed the symptoms to inflammation and described the condition as Covid-Associated Cystitis (CAC). Read more.

Source: Forbes, December 5, 2022

Overactive Bladder Linked to Multiple Unmet Socioeconomic Needs

Unmet socioeconomic needs had a significant association with overactive bladder (OAB), adding to evidence of a complex interaction between social determinants of health and OAB, researchers said. Stressors such as housing and food insecurity and concerns about personal health as much as tripled the odds of reported OAB symptoms. The stressors remained significant predictors for OAB after adjustment for multiple demographic and medical factors. Unmet socioeconomic needs had a stronger association with OAB with urge urinary incontinence (UUI, “wet” OAB), reported Elisabeth M. Sebesta, MD, of Vanderbilt University Medical Center in Nashville, Tennessee, and co-authors in the Journal of Urology. Read more.

Source: MedPage Today, December 1, 2022

Urinary Incontinence Poses Burden to Long-Term Care

The impact and management of urinary incontinence (UI) related to overactive bladder is a substantial burden to long-term care (LTC) residents and staff, according to a study published online July 1 in the Journal of Gerontological Nursing. Richard G. Stefanacci, D.O., from Thomas Jefferson University in Philadelphia, and colleagues assessed the impact of UI on residents, staff, care processes, and quality measures in LTC settings. The analysis included responses from directors of nursing who had worked for at least one year in a ≥100-bed facility. Read more.

Source: Health Day News, July 25, 2022

COVID-19 Infection Increases the Risk of New or Worsening OAB Symptoms

Patients with COVID-19 infection are at increased risk of developing new or worsening symptoms of overactive bladder (OAB), according to data presented at the American Urological Association’s annual meeting in 2022 in New Orleans, Louisiana. Ly Hoang Roberts, MD, of Oakland University, Royal Oak, Michigan, and colleagues noted that they were the first American group to identify de novo genitourinary symptoms, such as frequency, urgency, nocturia, and pain / pressure in people with previous COVID 19 infection. They called this condition COVID-19 associated cystitis (CAC). Read more.

Source: Community 99, May 15, 2022

Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). Read more.

Source: Business Wire, March 7, 2022

Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)

Urovant Sciences, Inc (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. Read more.

Source: BioSpace, December 23, 2020

New Research Takes P*** Out of Incontinence

Millions of people might eventually be spared the embarrassment and extreme isolation caused by wetting themselves, thanks to new research. One in every five people has a lower urinary tract disorder called overactive bladder which, for some, means not being able to hold in urine, needing to go to the toilet often, or waking in the night to empty their bladder. Some wear sanitary towels or disposable underwear, while others worry that even with absorbent underwear, they’ll smell of urine, so they choose instead to stay at home. Now, scientists at the University of Portsmouth have identified chemicals in urine that are specific to overactive bladder. The next step is to develop a gadget similar to a pregnancy test, to see if these chemical markers are present. Such a device is 12-24 months from clinical trials, but the early signs are encouraging. Read more.

Source: EurekAlert,, February 20, 2020

Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the approval of the Axonics r-SNM® System by the United States Food & Drug Administration (“FDA”) for the clinical indications of overactive bladder (“OAB”) and urinary retention. The FDA premarket approval (“PMA”) grants Axonics the right to market its product in the United States for the clinical indications of OAB (urinary urge incontinence and urinary urge frequency) as well as urinary retention, representing the largest segment of the market for SNM devices. The FDA approval follows the Company’s September approval for the clinical indication of fecal incontinence, which, according to published clinical studies, is a co-morbidity reported by as many as a third of patients presenting with urinary urge incontinence. Read more.

Source: Business Wire, November 14 2019